United Statesprotagonist-inc.com
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of peptide-based medicines for hematologic and inflammatory diseases. The company uses a proprietary platform to design constrained peptides that modulate validated biological targets.
Its lead wholly owned program is rusfertide (PTG-300), a hepcidin mimetic in late-stage development for polycythemia vera and other disorders of iron regulation. Protagonist also collaborates with Janssen on oral interleukin-23 receptor antagonists, including JNJ-2113 (formerly PN-235) for immune-mediated conditions. Additional pipeline candidates target gastrointestinal and systemic inflammatory pathways.
Protagonist is headquartered in the United States and conducts research and development across the U.S. and Australia.
ICONIC Phase 3: PASI100 rose to 49%/48% (ADVANCE 1/2) by Week52; placebo switchers matched. Adolescents: 57% PASI100, 86% PASI90 at 52w. No new safety signals; fewer AEs vs deucravacitinib.
First targeted oral IL‑23 receptor peptide approved for moderate‑to‑severe plaque psoriasis in adults and ≥12 (≥40kg). Once‑daily pill; ~70% IGA0/1, 55% PASI90 at Week16; safety like placebo.
Rusfertide shows promise in controlling hematocrit and reducing symptoms in polycythemia vera, with FDA review based on positive Phase 3 and long-term study data.
Rusfertide shows promise in controlling hematocrit and reducing phlebotomy in PV patients, meeting key endpoints in Phase 3 VERIFY study.
Rusfertide shows sustained hematocrit control and reduced phlebotomy need in polycythemia vera over 52 weeks, with a consistent safety profile.
